These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26805271)

  • 1. [The Clinical Role of the Neutrophil/Lymphocyte Ratio in Patients with Advanced Gastric Cancer Treated with Protein-Bound Polysaccharide K and Chemotherapy].
    Namikawa T; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Okamoto K; Kumon M; Kobayashi M; Hanazaki K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2081-3. PubMed ID: 26805271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
    Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Aug; 36(8):4237-41. PubMed ID: 27466538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
    Akagi J; Baba H
    Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
    Makiyama A; Kunieda K; Noguchi M; Kajiwara T; Tamura T; Takeda K; Sugiyama J; Minashi K; Moriwaki T; Sugimoto N; Nagase M; Negoro Y; Tsuda T; Shimodaira H; Okano N; Tsuji A; Sakai D; Yanagihara K; Ueda S; Tamura S; Otsu S; Honda T; Matsushita Y; Okuno T; Kashiwada T; Nozaki A; Ebi M; Okuda H; Shimokawa M; Hironaka S; Hyodo I; Baba E; Boku N; Muro K; Esaki T
    Gastric Cancer; 2018 Sep; 21(5):792-801. PubMed ID: 29353332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of polysaccharide k with S-1 based chemotherapy in advanced gastric cancer.
    Yoshikawa K; Shimada M; Kurita N; Sato H; Iwata T; Nishioka M; Morimoto S; Miyatani T; Komatsu M; And RN
    Hepatogastroenterology; 2013 Sep; 60(126):1387-90. PubMed ID: 23933930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of neutrophil to lymphocyte ratio in colorectal cancer patients receiving adjuvant chemotherapy combined with polysaccharide-K].
    Yoshioka S; Kubo M; Yanagisawa K; Hata T; Takiuchi D; Hamano R; Minohata J; Kashiwazaki M; Miki H; Tsujie M; Konishi M; Yano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2086-8. PubMed ID: 24394021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results].
    Yoshikawa T; Tsuburaya A; Saze Z; Aoyama T; Hasegawa S; Kanemoto A; Terashima M; Tahara H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1909-11. PubMed ID: 22202235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
    Kim JY; Do YR; Park KU; Kim JG; Chae YS; Kim MK; Lee KH; Ryoo HM; Bae SH; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):527-32. PubMed ID: 20461377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
    Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical development of S-1 (TS-1) for advanced gastric cancer].
    Wasaburo K; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Mihara S; Nakatani K; Nishimura K; Shimoda T; Azuma M; Katada C; Hanaoka N; Naruke A; Ryu T; Ishido K; Saigenji K
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():57-63. PubMed ID: 16897973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K].
    Totsuka O; Kawate S; Hirai K; Ogawa H; Toya H; Yoshinari D; Sunose Y; Takeyoshi I
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2525-8. PubMed ID: 24335363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count.
    Toge T; Yamaguchi Y
    Oncol Rep; 2000; 7(5):1157-61. PubMed ID: 10948356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
    Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Sugai H; Akaike H; Fujii H
    Oncology; 2008; 74(3-4):143-9. PubMed ID: 18708731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.
    Namikawa T; Munekage E; Munekage M; Maeda H; Yatabe T; Kitagawa H; Kobayashi M; Hanazaki K
    Oncology; 2016; 90(6):321-6. PubMed ID: 27225990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
    Takahari D; Hamaguchi T; Yoshimura K; Katai H; Ito S; Fuse N; Kinoshita T; Yasui H; Terashima M; Goto M; Tanigawa N; Shirao K; Sano T; Sasako M
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1423-8. PubMed ID: 20809123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer.
    Jeong JH; Lim SM; Yun JY; Rhee GW; Lim JY; Cho JY; Kim YR
    Oncology; 2012; 83(5):292-9. PubMed ID: 22964877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
    Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.